IP Library Granted Patent US 6,919,425
Granted Patent B2
US 6,919,425 · App. 09/899,376 · Granted Jul 19, 2005

Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery

Assignee: Board of Regents, The University of Texas System
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,919,425
App. No.
09/899,376
Granted
Jul 19, 2005
Kind
B2
Abstract

The present invention provides a tumor-homing peptide that can target cancer and or tumor tissues. The peptide is uptaken by certain specific cancer cell types. The invention describes methods to achieve targeted delivery of anticancer drugs conjugated to this peptide for anticancer therapy. The invention also describes methods for using the peptide for the diagnosis and imaging of cancer and tumor tissues.

Claims (15)

1. An isolated peptide that targets a tumor cell, wherein said peptide comprises the amino acid sequence of SEQ ID NO:1.

2. The peptide of claim 1 , consisting of SEQ ID NO:1.

3. A composition comprising:

a) an anti-cancer drug; and

b) a peptide that targets a tumor cell, wherein said peptide comprises the amino acid sequence of SEQ ID NO:1.

4. The composition of claim 3 , wherein said peptide consists of SEQ ID NO:1.

5. The composition of claim 3 , wherein said drug is a chemotherapeutic agent.

6. The composition of claim 3 , wherein said drug is a cytotoxic agent.

7. The composition of claim 3 , wherein said drug is an apoptotic agent.

8. The composition of claim 3 , wherein said drug is a DNA-damaging agent.

9. The composition of claim 3 , wherein said drug is plant alkaloid.

10. The composition of claim 3 , wherein said drug is cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chiorambucil, bisulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, transplatinum, 5-fluorouracil, vincristin, vinblastin or methotrexate.

11. The peptide of claim 1 , wherein said peptide is internalized by said tumor cell.

12. The composition of claim 3 , wherein said peptide is internalized by said tumor cell.

13. The composition of claim 9 , wherein said plant alkaloid is paclitaxel.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jan 26, 2018
From: UNIVERSITY OF TX MD ANDERSON CAN CTR
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045165/0975 →
CONFIRMATORY LICENSE Recorded Jan 9, 2018
From: MD ANDERSON CANCER CENTER
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 044578/0242 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2001
From: HONG, FRANK D.; CLAYMAN, GARY
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 012392/0573 →
Continuity (2)
Provisional Application 6021549100 · Jun 30, 2000
Related Publication 20020102265A1 · Aug 1, 2002